South Korea · Delayed Price · Currency is KRW Sam-A Pharm. Statistics
Total Valuation
Sam-A Pharm. has a market cap or net worth of KRW 100.16 billion. The enterprise value is 9.46 billion.
| Market Cap | 100.16B |
| Enterprise Value | 9.46B |
Important Dates
The next estimated earnings date is Tuesday, May 12, 2026.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Sam-A Pharm. has 6.10 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 6.10M |
| Shares Outstanding | 6.10M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 68.45% |
| Owned by Institutions (%) | n/a |
| Float | 1.93M |
Valuation Ratios
The trailing PE ratio is 7.74.
| PE Ratio | 7.74 |
| Forward PE | n/a |
| PS Ratio | 1.29 |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | 10.71 |
| P/OCF Ratio | 9.34 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 0.63, with an EV/FCF ratio of 1.01.
| EV / Earnings | 0.73 |
| EV / Sales | 0.12 |
| EV / EBITDA | 0.63 |
| EV / EBIT | 0.93 |
| EV / FCF | 1.01 |
Financial Position
The company has a current ratio of 9.78, with a Debt / Equity ratio of 0.03.
| Current Ratio | 9.78 |
| Quick Ratio | 8.58 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.44 |
| Debt / FCF | 0.74 |
| Interest Coverage | 24.89 |
Financial Efficiency
Return on equity (ROE) is 5.78% and return on invested capital (ROIC) is 6.35%.
| Return on Equity (ROE) | 5.78% |
| Return on Assets (ROA) | 2.77% |
| Return on Invested Capital (ROIC) | 6.35% |
| Return on Capital Employed (ROCE) | 4.71% |
| Weighted Average Cost of Capital (WACC) | 5.52% |
| Revenue Per Employee | 255.08M |
| Profits Per Employee | 42.43M |
| Employee Count | 300 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 2.06 |
Taxes
In the past 12 months, Sam-A Pharm. has paid 3.09 billion in taxes.
| Income Tax | 3.09B |
| Effective Tax Rate | 19.29% |
Stock Price Statistics
The stock price has decreased by -0.30% in the last 52 weeks. The beta is 0.24, so Sam-A Pharm.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -0.30% |
| 50-Day Moving Average | 15,978.60 |
| 200-Day Moving Average | 16,655.30 |
| Relative Strength Index (RSI) | 61.05 |
| Average Volume (20 Days) | 4,621 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sam-A Pharm. had revenue of KRW 77.80 billion and earned 12.94 billion in profits. Earnings per share was 2,120.00.
| Revenue | 77.80B |
| Gross Profit | 46.05B |
| Operating Income | 10.98B |
| Pretax Income | 16.03B |
| Net Income | 12.94B |
| EBITDA | 15.79B |
| EBIT | 10.98B |
| Earnings Per Share (EPS) | 2,120.00 |
Balance Sheet
The company has 97.64 billion in cash and 6.94 billion in debt, with a net cash position of 90.70 billion or 14,860.70 per share.
| Cash & Cash Equivalents | 97.64B |
| Total Debt | 6.94B |
| Net Cash | 90.70B |
| Net Cash Per Share | 14,860.70 |
| Equity (Book Value) | 228.11B |
| Book Value Per Share | 37,366.33 |
| Working Capital | 121.98B |
Cash Flow
In the last 12 months, operating cash flow was 10.72 billion and capital expenditures -1.37 billion, giving a free cash flow of 9.35 billion.
| Operating Cash Flow | 10.72B |
| Capital Expenditures | -1.37B |
| Depreciation & Amortization | 4.81B |
| Net Borrowing | -6.25B |
| Free Cash Flow | 9.35B |
| FCF Per Share | 1,532.45 |
Margins
Gross margin is 59.19%, with operating and profit margins of 14.11% and 16.63%.
| Gross Margin | 59.19% |
| Operating Margin | 14.11% |
| Pretax Margin | 20.61% |
| Profit Margin | 16.63% |
| EBITDA Margin | 20.29% |
| EBIT Margin | 14.11% |
| FCF Margin | 12.02% |
Dividends & Yields
This stock pays an annual dividend of 850.00, which amounts to a dividend yield of 5.13%.
| Dividend Per Share | 850.00 |
| Dividend Yield | 5.13% |
| Dividend Growth (YoY) | 6.25% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 37.73% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 5.11% |
| Earnings Yield | 12.92% |
| FCF Yield | 9.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 29, 2008. It was a forward split with a ratio of 1.02005.
| Last Split Date | Dec 29, 2008 |
| Split Type | Forward |
| Split Ratio | 1.02005 |
Scores
Sam-A Pharm. has an Altman Z-Score of 5.49 and a Piotroski F-Score of 4.
| Altman Z-Score | 5.49 |
| Piotroski F-Score | 4 |